<DOC>
	<DOCNO>NCT00828841</DOCNO>
	<brief_summary>This study test investigational drug , cetuximab , combination different chemotherapy drug lung cancer . The aim study determine drug combination look promise test . The study also look side effect may occur .</brief_summary>
	<brief_title>Phase 2b Study Cetuximab With Platinum-Based Chemo First Line Treatment Recurrent Advanced NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Written inform consent studyrelated activity Histologically cytologically confirm Stage IIIb cytologically document malignant pleural pericardial effusion , Stage IV , recurrent nonsmal cell lung cancer ( NSCLC ) resection radiation earlier stage disease Measurable evaluable disease ( per modify Response Evaluation Criteria Solid Tumors [ RECIST ] guideline ) Male female ≥ 18 year age Eastern Cooperative Oncology Group ( ECOG ) performance status 01 White blood count ≥ 3 x 10 ( 9 ) /L neutrophil ≥ 1.5 x 10 ( 9 ) /L , platelet count ≥ 100 x 10 ( 9 ) /L , hemoglobin ≥ 9.5 g/dL Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5 x ULN ≤ 5 x ULN patient liver mets Serum creatinine ≤ 1.25 x ULN Recovery prior surgery radiation Grade 1 good toxicity Women childbearing potential ( WOCBP ) fertile men partner childbearing potential must use adequate method contraception avoid pregnancy throughout study 4 wks study manner risk pregnancy minimize WOCBP must negative serum urine pregnancy test within 72 hrs prior start study medication accordance local regulation , whichever short duration WOCBP unwilling unable use acceptable method birth control avoid pregnancy entire study period 4 week study Women pregnant breastfeed Women positive pregnancy test screen prior study drug administration Sexually active fertile men use effective birth control partner woman childbearing potential Prior chemo advance NSCLC ; neoadjuvant postoperative adjuvant chemo allow complete least 12 month study entry Previous exposure epidermal growth factor receptor ( EGFR ) target therapy . Prior treatment monoclonal antibody target receptor EGFR , bevacizumab , allow complete &gt; 30 day prior randomization Treatment investigational agent ( ) within 4 week prior study entry Concurrent anticancer therapy ( chemotherapy , hormonal therapy , biologic targeted therapy ) protocol therapy Carcinoid , atypical carcinoid small cell lung cancer Symptomatic uncontrolled mets central nervous system Prior invasive malignancy require ongoing therapy within past year Active infection ( infection require intravenous [ IV ] antibiotic ) , include active tuberculosis , know declare HIV Myocardial infarction within 6 month prior study entry , uncontrolled congestive heart failure ; current Grade 3 4 cardiovascular disorder despite treatment Known allergic/hypersensitivity reaction component study treatment Peripheral neuropathy ≥ Grade 2 , assess Common Terminology Criteria Adverse Events , version 3.0 History significant neurologic psychiatric disorder include limited dementia , seizure , bipolar disorder Medical psychological condition would permit patient complete study sign inform consent Known drug abuse Patients race ethnic group eligible trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>